文献速递肿瘤 PET/CT

肺癌中成纤维细胞活化蛋白的表达及其与肿瘤葡萄糖代谢和组织病理学的相关性

Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-07

研究纳入2018年6月至2020年11月73例初诊肺癌患者,用免疫组化定量肿瘤FAP表达,用[18F]F-FDG PET/CT测量葡萄糖代谢参数及肿瘤最大径,分析FAP表达与代谢变量及组织病理学的相关性。结果显示97.3%(71/73)肺癌病灶FAP阳性,高于[18F]F-FDG PET/CT的87.7%(64/73)阳性率(χ2=4.818,P=0.028);12例早期腺癌中仅3例(25%)[18F]F-FDG阳性而10例(83.3%)FAP阳性。作者认为FAP在肺癌中广泛表达且在不同组织病理类型间差异大,FAP靶向显像可能对诊断肺癌尤其是早期腺癌敏感,但需进一步验证。

要点

  • 97.3%(71/73)肺癌病灶FAP表达阳性,高于[18F]F-FDG PET/CT的87.7%(64/73)阳性率(P=0.028)。
  • 12例早期腺癌中仅3例(25%)[18F]F-FDG阳性,而10例(83.3%)FAP阳性。
  • 高FAP水平见于100.0%鳞癌、85.7%腺癌、66.7%(4/6)大细胞神经内分泌癌和40.0%(4/10)小细胞肺癌(P<0.05)。

核心结论

  • FAP在肺癌中广泛表达且在不同组织病理类型间差异大,FAP高阳性率提示FAP靶向显像可能对诊断肺癌尤其是早期腺癌敏感,但需进一步验证。

研究设计与样本

  • 2018年6月至2020年11月纳入73例初诊肺癌患者,用免疫组化定量肿瘤FAP表达,用[18F]F-FDG PET/CT测量肿瘤葡萄糖代谢参数和肿瘤最大径,行单因素和多因素分析。

主要发现

  • 97.3%(71/73)肺癌病灶FAP表达阳性,高于[18F]F-FDG PET/CT的87.7%(64/73)阳性率(χ2=4.818,P=0.028)。
  • 12例早期腺癌中仅3例(25%)[18F]F-FDG PET/CT阳性,而10例(83.3%)FAP阳性。
  • FAP表达分为低水平(评分≤3)和高水平(评分>4),80.8%肿瘤为高FAP水平,19.2%为低FAP水平。
  • 高FAP水平见于100.0%鳞癌、85.7%腺癌、66.7%(4/6)大细胞神经内分泌癌和40.0%(4/10)小细胞肺癌(P<0.05)。
  • 在非黏液性腺癌病灶中,单因素分析显示FAP表达水平与肿瘤代谢参数(SUVmax、SUVmean、TLG)、肿瘤直径、肿瘤分级和病灶密度相关(P<0.05)。

局限性

  • 原文结论指出需用此类探针进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore the expression of fibroblast activation protein (FAP) in lung cancer (LC) and its correlation with tumor glucose metabolism and histopathology. METHODS: From June 2018 to November 2020, 73 patients with newly diagnosed LC were included. Immunohistochemical staining was used to quantify FAP expression in tumors. The histopathological type and tumor grade were determined via histopathological examination. The tumor glucose metabolism parameters and tumor maximal diameter were measured via [18F] F-FDG PET/CT. Univariate and multivariate analysis were performed to study the correlation of FAP expression levels with glucose metabolism variables and tumor histopathology. RESULTS: Positive FAP expression was observed in 97.3% (71/73) LC lesions, which was significantly higher than 87.7% (64/73) of [18F] F-FDG positivity observed on PET/CT (χ2 = 4.818, P = 0.028). In 12 early adenocarcinomas (ADCs), only three lesions (25%) were positive for [18F] F-FDG on PET/CT; however, 10 lesions (83.3%) were positive for FAP. When FAP expression was classified into low level (scores ≤ 3) and high level (scores > 4), high FAP level was found in 80.8% tumors and low FAP level in the other 19.2% tumors. High FAP level was identified in 100.0% of squamous cell carcinomas (SCCs), 85.7% of ADCs, 66.7% (4/6) of large cell neuroendocrine carcinomas (LCNCs), and 40.0% (4/10) of small cell lung cancers (SCLCs) (P < 0.05). In non-mucinous ADC lesions, on univariate analysis, FAP expression level showed a close relationship with tumor metabolism parameters (maximal standard uptake value (SUVmax), mean standard uptake value (SUVmean), and total lesion glycolysis (TLG)), tumor diameter, tumor grade, and lesion attenuation (P < 0.05). CONCLUSION: The present study demonstrates that FAP is widely expressed in LC and shows great variation in different histopathological types. A high positive rate of FAP expression implies that FAP-targeted imaging may be a sensitive modality for diagnosing LC, especially in early ADCs. Further validation with such probes is warranted.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen X, Liu X, Wang L, et al. Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology. Eur J Nucl Med Mol Imaging. 2022. PMID: 35254482. doi:10.1007/s00259-022-05754-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。